Orkla ASA (ORK)
Verdict history · ORK
Every call Verdix has made on ORK.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
Six weeks ago the panel was in a high-conviction WAIT at 103.6 NOK, with the Margin-of-Safety Hunter and Asymmetric Bargainer both hunting for a better entry. Since then, the Q2 earnings miss landed and a wave of analyst downgrades followed, which stripped away two bargain-hunting voices and brought in the Quality Rationalist's outright bearish dissent. The stock's 5.8% decline into the 95.15–99.13 no-trade zone — exactly the 'coiling' range the prior article flagged — has kept the panel in a BALANCED posture, but conviction dropped from HIGH to MEDIUM because the fundamental picture darkened while the technical damage remains unresolved.
See methodology for how verdicts are produced. Full track record →
The panel’s split verdict on ORK — and where they disagree.
The case for and against roughly balance — no clear edge at today's price.
OSL · Consumer Staples · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
BalancedMEDIUM confidence
Why
Orkla sits at 97.55 NOK after a Q2 miss and wave of downgrades, with four neutral voices waiting for the chart to resolve and one bear warning the moat is too narrow for the price. Insider buying is the strongest bullish signal on the table, but deteriorating earnings quality and an intact weekly downtrend keep the panel at BALANCED with medium conviction until either 106.70 or 95.15 breaks.Level to watch
Key support 96.39−1.2% from 97.55
Next catalyst
Breakout trigger: A weekly close above 106.70 — the monthly EMA20 and 38.2% Fibonacci retracement — would reclaim the monthly uptrend and validate that the Q2 miss was a one-off.The panel's take
Verdict: BALANCED · Conviction: MEDIUM · Last price: 97.55 · Changed from WAIT
Panel: 0 Bullish · 4 Neutral · 1 Bearish → BALANCED
What changed since 2026-08-15:
- Price: 103.6 → 97.55 (-5.84%)
- Panel: 0 of 6 → 0 of 5 now Bullish — composition also changed: added The Quality Rationalist; removed The Asymmetric Bargainer, The Margin-of-Safety Hunter
- Trigger: BUY trigger: a weekly close above 106.70 (monthly EMA20 / monthly Fib 38.2%) reclaiming the monthly uptrend and breaking the weekly Stage 4 sequence. SELL trigger: a weekly close below 95.15 (52‑week low / weekly swing low) confirming weekly Stage 4 breakdown with a path to 91.56 and the volume POC at 80.42.
- Verdict: WAIT → BALANCED
Six weeks ago the panel was in a high-conviction WAIT at 103.6 NOK, with the Margin-of-Safety Hunter and Asymmetric Bargainer both hunting for a better entry. Since then, the Q2 earnings miss landed and a wave of analyst downgrades followed, which stripped away two bargain-hunting voices and brought in the Quality Rationalist's outright bearish dissent. The stock's 5.8% decline into the 95.15–99.13 no-trade zone — exactly the 'coiling' range the prior article flagged — has kept the panel in a BALANCED posture, but conviction dropped from HIGH to MEDIUM because the fundamental picture darkened while the technical damage remains unresolved.
Price has closed at 97.55, below the prior trigger's 107.26 BUY threshold and above the 96.15 SELL trigger — but the selloff entered the 95.15 – 99.13 no‑trade zone that the article flagged as 'coiling,' and the Q2 earnings miss plus wave of analyst downgrades have materially darkened the fundamental picture, pulling four neutral voices toward the same wait‑and‑see posture despite the technical damage remaining unresolved. The Quality Rationalist's bearish dissent is the lone BUSINES objection — he sees a mediocre moat at a mediocre price — while the four neutrals all agree the business is sound but the timing is wrong with weekly Stage 4 still intact and no weekly close below 95.15 yet to confirm a full breakdown.
Key levels
Key levels · ORK
NOK · as of 2026-08-22Analyst consensus target 111.16 NOK · range 58.38–157.5
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support is the 96.39 weekly EMA200 cluster that held on 2026‑08‑16 and sits just below the 97.55 close, backed by the monthly EMA50 at 94.86 and the 91.56 monthly Fib 61.8% — all levels the weekly closed above on the as‑of date, leaving the bear breakdown unconfirmed. Key resistance at 99.13 (monthly Fib 50%) is immediate overhead, with the 106.30–108.65 EMA20/EMA50 zone representing the 'death zone' for any bear‑market rally; a close above 106.70 (monthly Fib 38.2% and monthly EMA20) would reclaim the monthly uptrend. The analyst consensus target of 111.16 sits above all these barriers, in the gap where the stock traded before the Q2 miss.
What legendary investors think
We ran Orkla ASA past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Moat CompounderValue/Quality/Moat⚫ NeutralLow
Signal: The CEO, chairman, and board members all bought shares on the open market after the Q2 miss — the CEO specifically purchased 15,000 shares at 104.70 NOK, above today's price. Conviction: Conviction sits at a guarded 55% because the OCF-to-net-income ratio of 0.86x means reported earnings outstrip actual cash generation, and I refuse to pay a premium for earnings I cannot fully trust.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: The EV/EBITDA of 17.74x is far less forgiving than the headline P/E of 10.6x, exposing the substantial net debt and intangible-heavy balance sheet that the market may be misreading as a bargain. Conviction: Confidence is held to 45% because the fundamental inputs are genuinely contradictory — the trailing P/E and FCF yield suggest cheapness while the EV/EBITDA, deteriorating earnings quality, and negative momentum all argue the opposite.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The Q2 revenue miss was a quarterly blip, not a structural collapse, and insiders — the CEO, chairman, and multiple board members — put real money in at prices above today's level after the earnings disappointment. Conviction: Conviction is capped at 50% by the dramatic drop in OCF/NI from 1.59x in FY2024 to 0.81x in FY2025 — without understanding why net income surged, I cannot trust the P/E that makes the stock look cheap.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The trailing P/E of 10.6x is the cheapest multiple this stock has carried in years for a business with sticky brands like Grandiosa and Toro that families buy every single week. Conviction: Conviction is held back because top-line growth is dead flat at 0.87% with revenue missing consensus in three of the last four quarters, and without a catalyst to reignite growth this remains a pure yield play with a capped upside.
The Quality RationalistMental Models/Quality🔴 BearishLow
Signal: Tangible book value is a mere 16.35 NOK per share against a stock trading at 97.55, meaning nearly six times the hard assets for a regional consumer-staples company with a narrow moat and no growth. Conviction: Conviction in the bearish call is tempered because the CEO buying shares with his own money signals an insider who knows the business best is betting on mean reversion, and dismissing that outright is arrogant.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- Every archetype agrees the Q2 earnings miss and subsequent analyst downgrades (UBS to Sell at 89 NOK) have materially darkened the fundamental picture and justify a wait-and-see posture.
- All five recognize the insider buying — CEO, chairman, and board members purchasing shares after the miss — as a powerful contrarian signal that at minimum means the selloff should not be taken at face value.
- All acknowledge the technical damage: weekly Stage 4 remains intact, and a weekly close below 95.15 (the 52-week low and swing low) would confirm a full breakdown with a path to 91.56 and potentially the volume POC at 80.42.
- The panel agrees the OCF-to-net-income deterioration (from 1.59x to 0.81x) is the single most important unresolved question in the numbers, casting doubt on the headline P/E of 10.6x.
The real debate
- The Quality Rationalist sees a mediocre moat at a mediocre price — a narrow regional brand portfolio that doesn't deserve the premium implied by the EV/EBITDA of 17.74x. The Moat Compounder, while also neutral, views the Nordic brand moat as genuine and durable, arguing that Grandiosa and Toro command real pricing power within Scandinavia even if the moat doesn't travel.
- The Forensic Skeptic treats the insider buying as the signal that matters most — insiders rarely buy into a falling knife without conviction. The Intrinsic-Value Modeler counters that insiders can be wrong about near-term fundamentals, and the analyst downgrades are data-driven contradictions that cannot be dismissed.
- The GARP Operator focuses on the trailing P/E of 10.6x as the cheapest in years and argues the market is pricing in permanent impairment. The Forensic Skeptic partially agrees on valuation but flags the earnings quality issue: if normalized earnings are closer to FY2024 levels, the P/E balloons to 15.7x and the bargain evaporates.
The question it comes down to: Does the insider buying after the Q2 miss signal that the selloff is an overreaction by a panicked market, or does the deteriorating earnings quality and intact weekly Stage 4 mean insiders are simply early in front of more pain?
The bottom line
- Breakout trigger: A weekly close above 106.70 — the monthly EMA20 and 38.2% Fibonacci retracement — would reclaim the monthly uptrend and validate that the Q2 miss was a one-off.
- Breakdown trigger: A weekly close below 95.15 — the 52-week low and swing low — confirms Stage 4 breakdown and opens a measured path to 91.56, then the high-volume POC at 80.42.
- Next catalyst: Q3 2026 earnings (likely October/November) will show whether revenue returns to growth and whether OCF again covers net income — both critical to restoring confidence in the headline P/E.
- Risk to monitor: Any dividend cut or major goodwill impairment on the 66%-intangible balance sheet would directly undermine the FCF-yield floor that four of five archetypes are relying on.
contact@verdixhq.com · Published 2026-08-22 · Prices as of 2026-08-22 · Time horizon: 3–12 months · No direct position held in ORK · ORK verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated